drugset
drugset / Trial / NCT03831711

68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer

NCT03831711 ↗

Phase 1/2 Completed 5 enrolled Andrei Iagaru General Electric · collab
NaSingle-groupOpen-labelDiagnostic

Summary

This trial studies how well 68-Ga RM2 works with PET/MRI in imaging patients with estrogen receptor-positive breast cancer. 68-Ga-RM2 is an agent used in diagnostic imaging.

Timeline

Start
2019-03-19
Primary completion
2021-11-15
Completion
2021-11-15

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-RM2 Diagnostic / imaging agent — Intravenous

Indications

estrogen-receptor positive breast cancer